Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT9N02I)

• DTT Name: Orexin receptor type 2 (HCRTR2) DTT Info
• Gene Name: HCRTR2

Molecule-Related Drug & Molecule List

1 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Suvorexant	DM0E6S3	Insomnia	7A00-7A0Z	Approved	[1]

4 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MIN-202	DMZFW8V	Major depressive disorder	6A70.3	Phase 2	[2]
MK-3697	DM347TQ	Insomnia	7A00-7A0Z	Phase 2	[3]
TAK-861	DMLGEQ7	Narcolepsy type 1	7A20.0	Phase 2	[4]
TAK-925	DM7N4H9	Narcolepsy	7A20	Phase 1	[5]

33 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1,2-diamino cyclopentane-based derivative 1	DMNH8GW	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 10	DM3ZF95	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 11	DMPZECW	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 12	DMWV53X	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 13	DM10UX4	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 14	DMTZDUV	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 15	DMBY65W	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 16	DMHEX1Q	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 17	DMBC9UK	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 18	DMCNQAF	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 19	DMCBPI4	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 2	DM7RG5I	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 20	DM9PHIK	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 21	DM5Y1DC	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 22	DMXRLI6	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 23	DM0HIQU	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 24	DMC26MT	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 25	DMEW0AT	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 26	DMTFG4J	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 27	DM5LQJW	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 29	DM5FVH0	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 3	DM143OK	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 30	DMZ4NJQ	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 31	DMVZ5EP	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 32	DMQX8SD	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 33	DMBOLSU	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 34	DMVHL3W	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 4	DMFBPSX	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 5	DMCP15K	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 6	DMJ4ACP	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 7	DMHIV24	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 8	DM7JX8U	N. A.	N. A.	Patented	[6]
1,2-diamino cyclopentane-based derivative 9	DM7I8ZV	N. A.	N. A.	Patented	[6]

8 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
EMPA	DM6O2BR	Discovery agent	N.A.	Investigative	[7]
JNJ-10397049	DMZ8M0K	Insomnia	7A00-7A0Z	Investigative	[8]
orexin-B	DM0XT69	Discovery agent	N.A.	Investigative	[9]
PMID15261275C1	DMFI4J6	Discovery agent	N.A.	Investigative	[10]
SB-334867	DMDZKWJ	Discovery agent	N.A.	Investigative	[11]
SB-408124	DMB8XZP	Discovery agent	N.A.	Investigative	[11]
TCS-OX2-29	DML8RTO	Discovery agent	N.A.	Investigative	[12]
[3H]SB-674042	DMO9L38	Discovery agent	N.A.	Investigative	[11]

References

• [1] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg Med Chem Lett. 2014 Oct 15;24(20):4884-90.
• [4] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [5] Molecular mechanism of the wake-promoting agent TAK-925. Nat Commun. 2022 May 25;13(1):2902.
• [6] Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
• [7] Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor. Br J Pharmacol. 2009 Apr;156(8):1326-41.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 322).
• [9] The signalling profile of recombinant human orexin-2 receptor. Cell Signal. 2008 Sep;20(9):1651-61.
• [10] Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4225-9.
• [11] Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison ... Mol Pharmacol. 2009 Sep;76(3):618-31.
• [12] N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4497-9.